NF-kB: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 5: | Line 5: | ||
*'''NF-kB1''' (synthesized as '''p105''' and processed to '''p50''')<br /> | *'''NF-kB1''' (synthesized as '''p105''' and processed to '''p50''')<br /> | ||
*'''NF-kB2''' (synthesized as '''p100''' and processed to '''p52''')<br /> | *'''NF-kB2''' (synthesized as '''p100''' and processed to '''p52''')<br /> | ||
*'''RelA''' (or '''p65''')<br /> | *'''RelA''' (or '''p65''' subunit of NF-kB)<br /> | ||
*'''RelB'''<br /> | *'''RelB'''<br /> | ||
*'''cRel'''. | *'''cRel'''. | ||
== Relevance == | == Relevance == | ||
NF-kB plays a critical role in cancer development and progression and may determine its response to therapy. NF-kB is a target for chemotherapeutic agents<ref>PMID:16673382</ref>. | NF-kB plays a critical role in cancer development and progression and may determine its response to therapy. NF-kB is a target for chemotherapeutic agents<ref>PMID:16673382</ref>. NF-kB is a critical link between inflammation and cancer<ref>PMID:20066113</ref>. | ||
</StructureSection> | </StructureSection> | ||